Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Formerly part of Thomson Reuters, Clarivate became an independent company in 2016 and went public on the New York Stock Exchange in 2019. The company is headquartered in London with operations in over 100 countries and a workforce of over 4,000 employees.
Clarivate serves a diverse clientele, ranging from academia, government, law, life sciences, and healthcare. Some of its most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™. These brands offer specialized services such as scientific and academic research, patent analytics, pharmaceutical and biotech intelligence, and IP management. Researchers and organizations globally rely on Clarivate's curated knowledge bases to accelerate innovation and bring new ideas to market more efficiently.
Recently, Clarivate has been recognized for its ongoing efforts and achievements. The company has made significant strides in the realm of cancer treatment research, particularly in the area of CAR T-cell therapies. According to a three-part report published by BioWorld™, Clarivate is exploring the rapid pipeline growth and clinical trials in CAR T therapy development in China. This report is part of the company’s commitment to providing valuable insights into groundbreaking treatments and their potential market impacts.
Additionally, Clarivate has launched key updates to its Cortellis CMC Intelligence™ solution, introducing a new post-approval variations module. This update assists pharmaceutical, biotech, and generics companies in streamlining regulatory tracking and optimizing lifecycle management for both small molecules and biologics.
The company also introduced Epidemiology Intelligence™, combining epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics. Another significant launch was the Trademark Watch Analyzer, an AI-enhanced trademark protection solution providing faster and more accurate answers to critical business questions by leveraging global trademark and case law data.
Financially, Clarivate reported a slight decrease in revenues for the first quarter of 2024, yet showed resilience and strategic focus on long-term growth. The company continues to invest in product development and operational initiatives to drive future organic revenue growth. Their financial stability is underscored by substantial cash flow and a clear strategy for debt management.
Clarivate’s strategic partnerships, such as the recent collaboration with HealthWise Data, further enhance its offerings by integrating Social Determinants of Health (SDoH) attributes into its Real-World Data repository, contributing to enhanced patient outcomes and healthcare equity.
For more information about Clarivate, its products, and services, visit www.clarivate.com.
Clarivate Plc (NYSE: CLVT) announced that its Executive Chairman Jerre Stead and CFO Richard Hanks will present at two upcoming virtual investor conferences. The presentations will take place at the BofA Securities Leveraged Finance Conference on November 30, 2021, at 8:15 am ET, and the Barclays Global Technology, Media, and Telecommunications Conference on December 7, 2021, at 3:35 pm ET. Webcasts for both events will be available for live access and replay. For more details, please visit Clarivate's website.
Clarivate Plc (NYSE:CLVT) has released its 2021 Highly Cited Researchers list, identifying 6,602 researchers globally, with 39.7% based in the United States, a decrease from previous years. Mainland China has seen significant growth, now boasting 935 researchers, nearly doubling its presence in four years. Key institutions include Harvard University with 214 researchers. This reflects a trend of globalization in research, with declines observed in the U.S. and U.K.
Clarivate Plc (NYSE: CLVT) announced that Executive Chairman Jerre Stead and CFO Richard Hanks will present at virtual investor conferences in November 2021. The first event is the RBC Capital Markets Global Technology Conference on November 17, 2021, at 9:35 AM ET, with a live webcast available for replay. The second event is the BofA Securities 2021 Leveraged Finance Conference on November 30, 2021, at 8:15 AM ET, also with a live webcast accessible for replay. For more details, visit clarivate.com.
Clarivate Plc (NYSE:CLVT) has been recognized by Forrester in their latest B2B2C Journey Mapping reports. These reports highlight the importance of transparency and trust in enhancing customer experiences. Clarivate's Customer Experience (CX) Services emphasizes the need for effective customer journey mapping, beginning with understanding customer feedback. The company also stresses the significance of recognizing partners' roles in customer experiences. This recognition underscores Clarivate's commitment to improving customer insights and driving business success.
Clarivate has partnered with the Biomedical Advanced Research and Development Authority (BARDA) to expedite the development of drug therapeutics that can serve as medical countermeasures (MCMs) for chlorine and sulfur mustard injuries. This collaboration will utilize machine learning and artificial intelligence to identify and repurpose existing FDA-approved drugs. Funding from BARDA will facilitate target identification and analyses, aiming to provide quicker responses to chemical exposure incidents. This initiative is part of BARDA's ReDIRECT program to enhance public health preparedness.
On November 2, 2021, Clarivate Plc (NYSE: CLVT) announced a Virtual Investor Day scheduled for November 9, 2021. The event will provide updates on the company's business, with presentations from 10:00 AM to 1:00 PM Eastern Time. Participants can join via webcast through the Clarivate Investor Relations website. A replay will also be available afterwards. Clarivate aims to accelerate innovation through trusted information and insights, helping clients navigate complex challenges in science and intellectual property.
Clarivate Plc (NYSE:CLVT) has been selected by Hewlett Packard Enterprise (HPE) as its IP lifecycle management partner. This collaboration enables HPE to utilize Clarivate's IPfolio and Innography to streamline administrative processes and enhance innovation strategies. HPE will benefit from improved management of its extensive patent and trademark portfolio, enabling faster decision-making and better resource allocation. The integration of CompuMark’s trademark research into IPfolio allows for comprehensive trademark management, reinforcing HPE's objectives in innovation and business transformation.
Clarivate Plc (NYSE:CLVT) announced a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares. The dividend will be paid in cash on December 1, 2021 to shareholders of record by the close of business on November 15, 2021. This declaration reflects the company's commitment to returning value to its shareholders.
Clarivate Plc (NYSE: CLVT) announced an extension of its share repurchase program through January 31, 2022, allowing for up to $250 million in buybacks. As of the announcement, $185 million remains available from the initial authorization, which was set to expire on October 31, 2021. This move aims to enhance shareholder value and demonstrates the company’s commitment to returning capital to investors. The decision reflects positive management confidence in the company's financial position and future growth prospects.
FAQ
What is the current stock price of Clarivate Plc (CLVT)?
What is the market cap of Clarivate Plc (CLVT)?
What does Clarivate do?
What are some of Clarivate’s trusted brands?
Where is Clarivate headquartered?
How did Clarivate become an independent company?
When did Clarivate go public?
What recent advancements has Clarivate made in the field of cancer treatment?
What is Cortellis CMC Intelligence™?
What is Epidemiology Intelligence™?
What is the purpose of the Trademark Watch Analyzer?
How does Clarivate enhance patient outcomes with HealthWise Data?
